TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10411245
Drug: Sarns oxygenator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarns oxygenator with 0.125 g of albumin/100 ml prime
Study: 10411245
Drug: Medtronic oxygenator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medtronic oxygenator with 0.0375 g of albumin/100 ml prime
Study: 10411245
Drug: Medtronic oxygenator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medtronic oxygenator with 0.125 g of albumin/100 ml prime
Study: 2083406
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid treatment (beclomethasone)
Study: 21334852
Drug: Taurine supplementation
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine supplementation (500 mg three times a day for 2 weeks)
Study: 19723429
Drug: Brushing for
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brushing for 180 seconds with 1.5 g Aquafresh Advanced dentifrice
Study: 19723429
Drug: Brushing for
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brushing for 120 seconds with 1.5 g Aquafresh Advanced dentifrice
Study: 9892228
Drug: Human regular
Normalized name: Human regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human regular insulin (0.075 U/kg lean body mass)
Study: 9892228
Drug: Insulin analog
Normalized name: insulin analog, glargine 300 UNT Pen Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin analog lispro (0.075 U/kg lean body mass)
Study: 6767404
Drug: Mestranol 50
Normalized name: Mestranol 50 microgram and norethindrone 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mestranol 50 micrograms and norethindrone 1 mg
Study: 6767404
Drug: Ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl estradiol 50 micrograms and norethindrone 1 mg
Study: 6767404
Drug: Ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl estradiol 35 micrograms and norethindrone 1 mg
Study: 6767404
Drug: Ethinyl estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl estradiol 30 micrograms and levonorgestrel 150 mg
Study: 24926949
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU of oral vitamin D2 daily (Arm A)
Study: 24926949
Drug: 1000 IU
Normalized name: D 1000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU daily in summer/fall and 2000 IU in winter/spring (Arm B)
Study: 23441533
Drug: Other treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatments for renal anemia
Study: 20212395
Drug: Nebulized L‐epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized L‐epinephrine (LE)
Study: 20212395
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BD) 200 mg
Study: 20212395
Drug: Intramuscular dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular dexamethasone (D) 0.6 mg/kg
Study: 18411237
Drug: Low-dose naloxone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose naloxone infusion (0.25 microg/kg per hour)
Study: 8390368
Drug: granisetron 3
Normalized name: granisetron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: granisetron 3 mg
Study: 9360939
Drug: Bacterial lysate
Normalized name: Thermus thermophilus lysate
DrugBank: Thermus thermophilus lysate (DB11227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacterial lysate treatment for three months
Study: 1942929
Drug: Intraarterial administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarterial administration of cisplatinum
Study: 1942929
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of cisplatinum
Study: 7461024
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg oral digoxin
Study: 7461024
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg oral digoxin
Study: 7461024
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg oral digoxin
Study: 7461024
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg oral digoxin
Study: 7461024
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg oral digoxin
Study: 23652826
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (simvastatin 40 mg and ezetimibe 10 mg daily)
Study: 23652826
Drug: Statin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin monotherapy (simvastatin 40 mg daily)
Study: 27736028
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and intracoronary melatonin
Study: 24167976
Drug: Hochuekkito (TJ‐41)
Normalized name: TJ-CD4B/ABL111
DrugBank: Givastomig (DB18618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hochuekkito (TJ‐41) 7.5 g/day for 7 days before surgery
Study: 19468545
Drug: dexametasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexametasone (8 mg)
Study: 9466094
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg kg‐1 h‐1)
Study: 9466094
Drug: Midazolam (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.06 mg kg‐1 h‐1)
Study: 9466094
Drug: Gamma-hydroxybutyrate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-hydroxybutyrate (20 mg kg‐1 h‐1)
Study: 3667022
Drug: Sucrose (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (81 +/- 18 g)
Study: 3667022
Drug: Caffeine (384
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (384 +/- 13 mg)
Study: 3667022
Drug: Sucrose (72
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (72 +/- 22 g) plus caffeine (396 +/- 29 mg)
Study: 29421772
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (CQ10) supplementation 100 mg/d for 12 weeks
Study: 26694632
Drug: 2% chamomile
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chamomile gel applied twice daily for 1 month
Study: 26694632
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied twice daily for 1 month
Study: 24462464
Drug: Nitroglycerin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin plus oral vinorelbine plus cisplatin
Study: 24462464
Drug: Oral vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine plus cisplatin alone (placebo)
Study: 20006908
Drug: Spectacles plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectacles plus patching >or=8 hours daily 6 days a week
Study: 20006908
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (daily and alternate-day occlusion)
Study: 9489595
Drug: Morphine delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine delivered over 40 seconds with a 5 min lockout interval
Study: 9489595
Drug: Morphine delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine delivered over 5 minutes with a 1 min lockout interval
Study: 7827744
Drug: Intermittent pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pneumatic compression (IPC) twice weekly for one hour each session
Study: 3413461
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg slow-release pindolol once daily
Study: 3413461
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg pindolol three times daily
Study: 20616787
Drug: Watermelon supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watermelon supplementation (L-citrulline/L-arginine, 2.7 g/1.3 g/day)
Study: 18221288
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg udenafil
Study: 21934637
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg udenafil
Study: 19101739
Drug: ART (Atraumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART (Atraumatic Restorative Treatment)
Study: 10925662
Drug: EHF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHF therapy + magnetotherapy + drugs
Study: 10925662
Drug: Standard drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug therapy
Study: 14621839
Drug: 3 pulses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 pulses of 8 mg/kg methylprednisolone (MPS) in an alternate‐day regimen (total dose 25 mg/kg in 1 week)
Study: 14621839
Drug: 5 daily
Normalized name: Alberto VO5 Daily Revitalizing Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 daily pulses of 3 mg/kg MPS (total dose 17 mg/kg)
Study: 12000000
Drug: Easyhaler (budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Easyhaler (budesonide 800 microg day(-1), 200 g dose(-1), two inhalations twice daily for 12 weeks)
Study: 12000000
Drug: Turbuhaler (budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbuhaler (budesonide 800 microg day(-1), 200 g dose(-1), two inhalations twice daily for 12 weeks)
Study: 2271378
Drug: Frusemide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 40 mg (F)
Study: 2271378
Drug: Frusemide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 40 mg in combination with triamterene 50 mg (F+T)
Study: 25832102
Drug: Single MenC-CRM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single MenC-CRM dose at 3 months
Study: 25832102
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of MenC-CRM at 3 and 4 months
Study: 25832102
Drug: Single MenC-polysaccharide-TT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single MenC-polysaccharide-TT dose at 3 months
Study: 25832102
Drug: No MenC
Approvals — FDA: no, EMA: no, PMDA: no
Description: No MenC doses
Study: 22457418
Drug: Lipid emulsion
Normalized name: propofol lipid emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid emulsion (LPD) group received 100 mL of a 20% soybean oil emulsion for 7 days after esophagectomy.
Study: 22457418
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received parenteral feeding with a glucose-based solution only.
Study: 17284127
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day of aripiprazole
Study: 17284127
Drug: 6 mg/day
Normalized name: EMSAM 6 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/day of risperidone
Study: 3497780
Drug: Sustained-release tiaprofenic
Normalized name: tiaprofenate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release tiaprofenic acid 600 mg once daily
Study: 3497780
Drug: Standard tiaprofenic
Normalized name: tiaprofenate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard tiaprofenic acid 300 mg tablets twice daily
Study: 3548295
Drug: pre drug
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: pre drug control
Study: 21247247
Drug: Candesartan (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (up to 12 mg/day)
Study: 21247247
Drug: Amlodipine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (up to 10 mg/day)
Study: 17701889
Drug: NN414 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NN414 1.5 mg/kg
Study: 17701889
Drug: NN414 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NN414 4.5 mg/kg
Study: 17701889
Drug: NN414 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: NN414 10 mg/kg
Study: 17701889
Drug: NN414 (1.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NN414 (1.5, 4.5, and 10 mg/kg)
Study: 11727838
Drug: Oral Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Methotrexate (7.5 mg/week) combined with Naproxen (1000 mg/day)
Study: 11727838
Drug: Naproxen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (1000 mg/day) alone
Study: 9859964
Drug: N-acetylcysteine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (3 g of the 20% liquid solution) 1 hour before each dose of TMP-SMX (trimethoprim 80 mg, sulfamethoxazole 400 mg) twice daily
Study: 2681559
Drug: 4x1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4x1 g ampicillin intravenously over 3 days
Study: 28960033
Drug: DA-9601 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-9601 (3 times daily for 2 weeks)
Study: 28960033
Drug: DA-5204 (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-5204 (twice daily for 2 weeks)
Study: 10168895
Drug: Laser photocoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser photocoagulation and aspirin treatment
Study: 27397060
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus vildagliptin 100 mg (InsV)
Study: 27397060
Drug: Insulin alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin alone (Ins)
Study: 25418987
Drug: PEG-asparaginase (Oncaspar®)
Normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-asparaginase (Oncaspar®) 1,000 IU/m²/dose administered intramuscularly at 2 or 6 weeks intervals for a total of 30 weeks
Study: 25418987
Drug: Erwinase therapy
Normalized name: Erwinaze
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erwinase therapy
Study: 19105270
Drug: Chinese traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese traditional medicine (oral administration)
Study: 19105270
Drug: Celecoxib and
Normalized name: amlodipine and celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib and glucosamine hydrochloride (oral administration)
Study: 11284464
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care medications
Study: 7870724
Drug: Radionuclide methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radionuclide methods (infusion dynamic ureteroscintigraphy, dynamic and static scintigraphy of the kidneys, radionuclide renography)
Study: 25058845
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (FF/VI), 100/25 μg, delivered via ELLIPTA dry powder inhaler, administered once daily
Study: 25058845
Drug: Tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotropium bromide (TIO), 18 μg, administered once daily
Study: 19923528
Drug: IV propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV propofol infusion (2.4 mg/kg)
Study: 15477492
Drug: Randomized study
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized study of two regimens for the last 4 months of treatment (n = 1,075)
Study: 15477492
Drug: Twice-weekly rifabutin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly rifabutin-containing regimen for HIV-infected tuberculosis (n = 169)
Study: 11452678
Drug: Amoxicillin clavulanate
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin clavulanate (875 mg twice daily)
Study: 9549518
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IV Ig) treatment (0.4 g/kg for 5 consecutive days)
Study: 9549518
Drug: IV Ig
Normalized name: IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Ig maintenance treatment (one infusion every week for 2-4 years)
Study: 9549518
Drug: Incidental IV
Normalized name: POTASSIUM NITRATE 3.75 g in 100 g / SODIUM MONOFLUOROPHOSPHATE 0.76 g in 100 g / CETYLPYRIDINIUM CHLORIDE 0.3 g in 100 g DENTAL PASTE, DENTIFRICE [Unidental All CareToothpaste]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incidental IV Ig treatment when muscle strength deteriorated
Study: 8311557
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - transdermal oestradiol patches twice weekly for 48 weeks plus norithisterone tablets when clinically indicated
Study: 28208713
Drug: Encapsulated fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated fruit and vegetable juice concentrate (6 capsules daily for 8 weeks)
Study: 19106250
Drug: 24-h fast
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-h fast with acipimox (250 mg)
Study: 14746858
Drug: rIFN-gamma (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN-gamma (0.2 mg, subcutaneously every other day for 12 months)
Study: 3092711
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin patches (5, 10, and 20 mg per 24 hours)
Study: 19064019
Drug: Rosuvastatin (1:1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (1:1 dose ratio)
Study: 19064019
Drug: Rosuvastatin (1:2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (1:2 dose ratio)
Study: 19064019
Drug: Rosuvastatin (1:4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (1:4 dose ratio)
Study: 19064019
Drug: Atorvastatin (1:1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (1:1 dose ratio)
Study: 19064019
Drug: Atorvastatin (1:2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (1:2 dose ratio)
Study: 19064019
Drug: Atorvastatin (1:4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (1:4 dose ratio)
Study: 11072457
Drug: 2-mg sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mg sublingual nicotine tablets
Study: 4028617
Drug: Amoxycillin 375
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 375 mg
Study: 4028617
Drug: Amoxycillin 750
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 750 mg
Study: 4028617
Drug: Amoxycillin 1500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 1500 mg
Study: 389824
Drug: Bacampicillin 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacampicillin 1600 mg
Study: 29732978
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TXA) 4 g for 1 hour followed by 1 g over 6 hours infusion
Study: 24929455
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (1 injection of methylprednisolone acetate)
Study: 22681971
Drug: 0.2 μg/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 μg/kg/h intravenous dexmedetomidine
Study: 22681971
Drug: 0.4 μg/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 μg/kg/h intravenous dexmedetomidine
Study: 22681971
Drug: 0.6 μg/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 μg/kg/h intravenous dexmedetomidine
Study: 15677598
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy plus medication
Study: 9934807
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg per day
Study: 268332
Drug: Chlorhexidine mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine mouthrinse once daily (Group A in maxillary areas)
Study: 268332
Drug: Localized plaque
Normalized name: Plaquenil
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Localized plaque accumulation with no oral hygiene (control)
Study: 28275131
Drug: Catechin beverage
Normalized name: catechin
DrugBank: Cianidanol (DB14086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Catechin beverage (615 mg catechin and 77 mg caffeine)
Study: 28275131
Drug: Placebo beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo beverage (82 mg caffeine)
Study: 28275131
Drug: Catechin beverage
Normalized name: catechin
DrugBank: Cianidanol (DB14086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Catechin beverage (daily ingestion for 5 weeks)
Study: 28275131
Drug: Placebo beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo beverage (daily ingestion for 5 weeks)
Study: 21342355
Drug: 20% olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% olive oil-based intravenous lipid emulsion (ILE)
Study: 21342355
Drug: 20% soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% soybean oil-based intravenous lipid emulsion (ILE)
Study: 19226569
Drug: 1,450 nm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,450 nm diode laser treatment
Study: 17126585
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose corticosteroid treatment (8-12 weeks)
Study: 11322354
Drug: Fibromyalgia Treatment
Normalized name: Aconitum napellus/Arnica montana Radix/Autumn Crocus/Barberry/Bryonia/Devil's Claw Root/Marsh Tea/Rhododendron Chrysanthum/Rhus Toxicodendron/Valerian/Woody Nightshade 4 X-3 X-6 X-6 X-4 X-6 X-6 X-6 X-4 X-2 X-6 X Oral Tablet, Disintegrating [FIBROMYALGIA SYMPTOM RELIEF]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibromyalgia Treatment Program
Study: 9385869
Drug: Invisible spatial
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invisible spatial transformations with varying orientation cues, path of motion, and amount of transformation; specific details on dosage and duration not applicable.
Study: 7899788
Drug: Albendazole 800
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 800 mg x 3 daily
Study: 7899788
Drug: Albendazole 1200
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 1200 mg x 3 daily